Business Description

The company’s segments include Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. Analytical Instruments offers instruments, consumables, and software that can be used in various settings, including in the lab, production line, and field.

The Life Sciences Solutions segment includes a range of consumables, instruments, and reagents used in medical and biological research. It also supports the discovery and production of new drugs and vaccines. Specialty Diagnostics offers diagnostic test kits, instruments, culture media, and associated products that help improve the accuracy and speed of diagnosis. Laboratory Products and Services includes everything necessary for a laboratory. This includes self-manufactured and sourced products available to customers in research, academia, government, industrial and healthcare settings. The company was established in Waltham, MA on October 11, 1960.

Key Financials

Revenue (US$ Mn)

• US$ 39,211 Mn was Thermo Fisher Scientific, Inc.’s annual revenue in 2021, a 21.71% increase from 2020 figures
• Thermo Fisher Scientific, Inc. indexed a 26.14% increase in annual revenues from 2019, amounting to US$ 32,218 Mn in 2020
• Thermo Fisher Scientific, Inc. generated total revenue of US$ 25,542 Mn in 2019
• Annual revenue of US$ 24,358 Mn was indexed by Microsoft Corporation in 2018

Operating Income(US$ Mn)

• US$ 10,028 Mn was the operating income generated by Thermo Fisher Scientific, Inc. in 2021
• Thermo Fisher Scientific, Inc.’s operating income for 2020 was US$ 7,794 Mn, a 69.66% increase from 2019
• From 2018’s operating incomes, Thermo Fisher Scientific, Inc. registered a 21.44% increase in 2019, amounting to US$ 4,594 Mn
• An operating income of US$ 3,783 Mn was generated in 2018 by Thermo Fisher Scientific, Inc.

Net Income(US$ Mn)

• Thermo Fisher Scientific, Inc.’s net income for 2021 was US$ 7,728 Mn, a 21.22% increase from the 2020
• The net income generated by Thermo Fisher Scientific, Inc. in 2020 was US$ 6,375 Mn
• At a 25.8% increase from, Thermo Fisher Scientific, Inc.’s net income of US$ 3,696 Mn was indexed in 2019
• Thermo Fisher Scientific, Inc. generated a net income of US$ 2,938 Mn in 2018

Operating Margin %

• 26% was Thermo Fisher Scientific, Inc.’s operating margin in 2021, a 5.79% increase from 2020 figures
• Thermo Fisher Scientific, Inc. indexed a 34.44% increase in operating margins from 2019, amounting to 24% in 2020
• Thermo Fisher Scientific, Inc. generated an operating margin of 18% in 2019
• An operating margin of 16% was indexed by Microsoft Corporation in 2018

Gross Margin %

• 20% was the gross margin generated by Thermo Fisher Scientific, Inc. in 2021
• Thermo Fisher Scientific, Inc.’s gross margin for 2020 was 20%, a 37.36% increase from 2019
• From 2018’s gross margins, Thermo Fisher Scientific, Inc. registered a 19.4% increase in 2019, amounting to 14%
• A gross margin of 12% was generated in 2018 by Thermo Fisher Scientific, Inc.

SWOT Analysis

Strengths

Diversified business operations to enhance its customer base

Thermo Fisher Scientific’s well-diversified operations reduce the risk of being too dependent on one or a few segments. The company has four segments: Life Sciences Solutions and Specialty Diagnostics and Analytical Instruments. Laboratory Products and services offer a wide range of services and products that can be sourced or self-manufactured. Thermo Fisher Scientific’s Life Sciences Solutions segment offers a wide range of consumables, instruments, and reagents for medical and biological research. It also supports the discovery, production, and diagnosis of diseases. The company’s specialty diagnostics segment offers a variety of reagents and culture media, as well as instruments and test kits.

This allows customers to be served in the healthcare, industrial, pharmaceutical, and food safety industries. Thermo Fisher Scientific’s analytical instrument segment offers instruments, consumables, and software that can be used in a variety of settings, including in the lab, on the production line, and out in the field. The company’s revenue came from Laboratory Products and Services at 39.7%. Life Sciences Solutions was second at 25.7%, Analytical Instruments at 20.7%, and Specialty Diagnostics at 13.9%. Its diverse business operations enable it to provide a wide range of services and improve its financial performance.

Financial performance

In FY 2019, the company’s financial performance improved. The company’s financial performance has improved, allowing it to return higher dividends to shareholders and attract more investments. This allows the company to allocate sufficient funds to cover its operational costs. The company’s revenue for FY2019 was US$25542 million, compared to US$24 358 million in FY2018. This 4.9% increase is attributed to the company’s increased sales.

The company saw increased demand for its products, which led to an increase in sales to customers in all of its primary markets. The company’s FY2019 operating income was US$4,594 million, compared to US$3,783 million in FY2018 which increased by 27.5%. Its net income increased by 26 i> to US$3,696 million in FY2019, from 2,938 million in FY2018.

Product innovation is possible thanks to a strong focus on R&D

Thermo Fisher Scientific’s focus is on research and development (R&D). The company is actively involved in the development of new products and improving the use of existing products and services. Thermo Fisher Scientific has added several products to its product line through its R&D activities. This could increase the company’s revenue.

The company has taken several steps to improve its R&D activities and offer new products. The company spent 3.9% of its total revenue on R&D during FY2019. This represented US$1,003million. A strong R&D focus allows for product innovation, which gives the company a competitive advantage over its competitors in the market.

Get this premium content

The Premium data is Locked

Buy Now to Unlock Premium Data

Request Sample Data